Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Familial Adenomatous Polyposis (FAP) is an autosomal dominant disorder characterized by the
formation of multiple adenomatous colorectal polyps usually in the teenage years. Virtually,
all patients with FAP will develop colorectal cancer on average by the 5th decade of life if
prophylactic surgery is not performed. Besides, these individuals must have lifelong cancer
surveillance of the remaining colorectum or ileum.
Use of nonsteroidal anti-inflammatory drug (NSAID), such as sulindac, or celecoxib, which
selectively inhibits prostaglandin synthesis primarily via the inhibition of cyclogenase-2
(COX-2) have been shown to reduce the incidence and induce regression of adenomas in the
rectum of patients with FAP. However, use of NSAIDs and COX-2 inhibitors is associated with
significant comorbidity including renal and gastric toxicity and increased risk of vascular
events. Therefore, identification of a chemopreventive agent that would have similar efficacy
but less toxicity would enhance our ability to treat these patients. Therefore the following
specific aim has been proposed:To determine in a randomized, double-blinded,
placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal
adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in patients
with FAP.